XM does not provide services to residents of the United States of America.
R
R

RECSilicon

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

Italy - Factors to watch on Nov. 11

CORRECTED-Italy - Factors to watch on Nov. 11 Corrects number in paragraph 6 to million from billion The following factors could affect Italian markets on Monday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy. New items are marked with (*). For a complete list of diary events in Italy please click on IT/DIA . COMPANIES ENEL ENEI.MI Brazil's solicitor general's office said on Friday that it is suing the Italian energy group for 260 million reais ($45.12 milli
A
B
E
E
G
H
L
R
S
T
U
A
B
B
D
J
M
R
R
I
U

Italy's Recordati sees no impact from potential US pharma tariffs

UPDATE 1-Italy's Recordati sees no impact from potential US pharma tariffs Adds from paragraph 4 background, CFO quotes By Giancarlo Navach MILAN, Nov 7 (Reuters) - Italian drug maker Recordati RECI.MI is not concerned about potential new U.S. tariffs under president-elect Donald Trump as it expects them to have no impact on its rare diseases business, the company's chief financial officer said on Friday.
R
S

Italy's Recordati sees no impact from potential U.S. pharma tariffs

Italy's Recordati sees no impact from potential U.S. pharma tariffs By Giancarlo Navach MILAN, Nov 7 (Reuters) - Italian drug maker Recordati RECI.MI is not afraid of potential new U.S. tariffs under president-elect Donald Trump as it expects them to have no impact on its rare diseases business, the company's chief financial officer said on Friday.
R

Italian pharmaceutical firm Recordati's 9-month profit leaps 11.8%

Italian pharmaceutical firm Recordati's 9-month profit leaps 11.8% Nov 8 (Reuters) - Italian drug maker Recordati RECI.MI posted on Friday a 11.8% jump in its nine-month core profit (EBITDA) boosted by strong business momentum in both specialty and primary care and rare diseases segments. The Milan-based company January-September core profit totalled 665.7 million euros ($717.69 million), while its revenue stood at 1.74 billion euros, up 12% year-on-year.
R

Recordati 9M Adj. Net Profit EUR 445.4 Mln

BRIEF-Recordati 9M Adj. Net Profit EUR 445.4 Mln Nov 8 (Reuters) - Recordati Industria Chimica e Farmaceutica SpA RECI.MI : 9M REVENUE EUR 1.74 BILLION 9M EBITDA EUR 665.7 MILLION 9M ADJUSTED NET PROFIT EUR 445.4 MILLION PROPOSES INTERIM DIVIDEND FOR 2024 OF EUR 0.60 PER SHARE CONFIRMS 2024 OUTLOOK, EXCLUDING CONTRIBUTIONS FROM ENJAYMO DEAL, EXPECT
R

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.